News

Regeneron is said to have declined a higher bid for 23andMe after Wojcicki's offer
Regeneron Pharmaceuticals (NASDAQ:REGN) has reportedly declined to submit a higher bid for 23andMe (OTC:MEHCQ) after a ...
Regeneron declines to make higher bid for 23andMe after Wojcicki's $305 million offer
Regeneron Pharmaceuticals has declined to submit a new bid for genetic testing company 23andMe exceeding its original winning ...
iHLS Israel Homeland Security3h
23andMe DNA Database Acquired, Prioritizing Privacy and Transparency
The genetic data of millions of individuals who once used 23andMe’s DNA testing services has officially changed hands. The ...
BioPharma Dive56m
FDA clears CSL’s swelling disease drug; Regeneron loses 23andMe auction
The agency cleared CSL’s hereditary angioedema drug days after “resource constraints” delayed a rival medicine. Elsewhere, ...
BioWorld17h
23andme founder-led group outbids Regeneron for company
The 23andme Holding Co.’s saga came full circle with founder Anne Wojcicki regaining control of the bankrupt genetic testing ...
23andMe Under Fire as Customers Demand DNA Deletion Amid Bankruptcy and Privacy Fears
A growing number of 23andMe users are distancing themselves from the once-popular genetic testing company, as mounting ...
23andMe’s DNA Data Soars in Value With New $305 Million Bid
Bankrupt genetic analysis company 23andMe will hold a second auction for its cache of DNA data with an opening bid of $305 ...
23andMe Customers Did Not Expect Their DNA Data Would Be Sold, Lawsuit Claims
The genetic-testing company, which collected DNA data from users, is for sale in bankruptcy court. Now, 27 states and the ...
Anne Wojcicki's bid to buy back 23andMe may not end a legal fight over DNA customer data
Anne Wojcicki’s winning bid to reclaim control of 23andMe doesn’t necessarily end the fight over what happens to the DNA of ...